4//SEC Filing
Lacey John III 4
Accession 0001493152-24-038887
CIK 0000315545other
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 8:01 PM ET
Size
6.1 KB
Accession
0001493152-24-038887
Insider Transaction Report
Form 4
Lacy John III
Director
Transactions
- Award
Series D-1 Convertible Preferred Stock
2024-09-30+179,592→ 179,592 totalFrom: 2024-09-30→ Common Stock (1,795,920 underlying)
Footnotes (2)
- [F1]Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
- [F2]The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
Documents
Issuer
PROVECTUS BIOPHARMACEUTICALS, INC.
CIK 0000315545
Entity typeother
Related Parties
1- filerCIK 0001739761
Filing Metadata
- Form type
- 4
- Filed
- Sep 29, 8:00 PM ET
- Accepted
- Sep 30, 8:01 PM ET
- Size
- 6.1 KB